Market Exclusive

Analyst Activity – William Blair Reiterates Outperform on Aduro Biotech (NASDAQ:ADRO)

Analyst Ratings For Aduro Biotech (NASDAQ:ADRO)

Today, William Blair reiterated its Outperform rating on Aduro Biotech (NASDAQ:ADRO).

There are 8 buy ratings on the stock.

The current consensus rating on Aduro Biotech (NASDAQ:ADRO) is Buy (Score: 3.00) with a consensus target price of $20.00 per share, a potential 81.82% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Aduro Biotech (NASDAQ:ADRO)
Aduro Biotech (NASDAQ:ADRO) has insider ownership of 6.60% and institutional ownership of 35.05%.

Recent Trading Activity for Aduro Biotech (NASDAQ:ADRO)
Shares of Aduro Biotech closed the previous trading session at with shares trading hands.

Exit mobile version